Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ADRB3 | P13945 | 18/20 | 0.47 |
| ▸ | ADRB1 | P08588 | 12/20 | 0.47 |
| ▸ | ADRB2 | P07550 | 6/20 | 0.47 |
| ▸ | MEN1 | O00255 | 1/20 | 0.46 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.46 |
| ▸ | LMNA | P02545 | 1/20 | 0.46 |
| ▸ | TP53 | P04637 | 1/20 | 0.46 |
| ▸ | GAA | P10253 | 1/20 | 0.46 |
| ▸ | MAPT | P10636 | 1/20 | 0.46 |
| ▸ | HTT | P42858 | 1/20 | 0.46 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.46 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7254600 | 1.00 | ADRB3 (0.47) | ADRB3ADRB1ADRB2MEN1ALDH1A1 | |
| SCHEMBL7044530 | 0.93 | ADRB3 (0.43) | ADRB3ADRB1ADRB2MEN1ALDH1A1 | |
| SCHEMBL7044134 | 0.93 | ADRB3 (0.49) | ADRB3ADRB1ADRB2 | |
| SCHEMBL7042476 | 0.92 | ADRB3 (0.54) | ADRB3ADRB1ADRB2MEN1ALDH1A1 | |
| SCHEMBL7041267 | 0.91 | ADRB3 (0.54) | ADRB3ADRB1ADRB2MEN1ALDH1A1 | |
| SCHEMBL7044653 | 0.91 | ADRB3 (0.48) | ADRB3ADRB1ADRB2MEN1ALDH1A1 | |
| SCHEMBL7248400 | 0.89 | ADRB3 (0.54) | ADRB3ADRB1ADRB2MEN1ALDH1A1 | |
| SCHEMBL7254607 | 0.85 | ADRB3 (0.49) | ADRB3ADRB1ADRB2MEN1ALDH1A1 | |
| SCHEMBL7042585 | 0.84 | ADRB3 (0.51) | ADRB3ADRB1ADRB2 | |
| SCHEMBL7042681 | 0.84 | ADRB3 (0.45) | ADRB3ADRB1ADRB2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20030073846-A1 | Aminoalcohol derivatives | FUJISAWA PHARMACEUTICAL CO., LTD. (JP) | 2003-04-17 | — | — | US | disclosed |
| EP-1292564-A2 | AMINOALCOHOL DERIVATIVES | FUJISAWA PHARMACEUTICAL CO., LTD. (JP) | 2003-03-19 | — | — | EP | disclosed |
| WO-2001062705-A2 | AMINOALCOHOL DERIVATIVES | FUJISAWA PHARMACEUTICAL CO., LTD. (JP) | 2001-08-30 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030073846-A1 | Aminoalcohol derivatives | XDH, ADH1A, ADRB1 | ADRB3 20/4885ADRB1 3/4885ADRB2 4/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.